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People with reduced kidney function have increased cardiovascular disease (CVD) risk. We
present a policy model that simulates individuals’ long-term health outcomes and costs to
inform strategies to reduce risks of kidney and CVDs in this population.
Methods and findings
We used a United Kingdom primary healthcare database, the Clinical Practice Research
Datalink (CPRD), linked with secondary healthcare and mortality data, to derive an open
2005–2013 cohort of adults (�18 years of age) with reduced kidney function (�2 measures
of estimated glomerular filtration rate [eGFR] <90 mL/min/1.73 m2�90 days apart). Data on
individuals’ sociodemographic and clinical characteristics at entry and outcomes (first occur-
rences of stroke, myocardial infarction (MI), and hospitalisation for heart failure; annual kid-
ney disease stages; and cardiovascular and nonvascular deaths) during follow-up were
extracted. The cohort was used to estimate risk equations for outcomes and develop a
chronic kidney disease–cardiovascular disease (CKD–CVD) health outcomes model, a
Markov state transition model simulating individuals’ long-term outcomes, healthcare costs,
and quality of life based on their characteristics at entry. Model-simulated cumulative risks
of outcomes were compared with respective observed risks using a split-sample approach.
To illustrate model value, we assess the benefits of partial (i.e., at 2013 levels) and optimal
(i.e., fully compliant with clinical guidelines in 2019) use of cardioprotective medications.
The cohort included 1.1 million individuals with reduced kidney function (median follow-up
4.8 years, 45% men, 19% with CVD, and 74% with only mildly decreased eGFR of 60–89
mL/min/1.73 m2 at entry). Age, kidney function status, and CVD events were the key
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determinants of subsequent morbidity and mortality. The model-simulated cumulative dis-
ease risks corresponded well to observed risks in participant categories by eGFR level.
Without the use of cardioprotective medications, for 60- to 69-year-old individuals with mildly
decreased eGFR (60–89 mL/min/1.73 m2), the model projected a further 22.1 (95% confi-
dence interval [CI] 21.8–22.3) years of life if without previous CVD and 18.6 (18.2–18.9)
years if with CVD. Cardioprotective medication use at 2013 levels (29%–44% of indicated
individuals without CVD; 64%–76% of those with CVD) was projected to increase their life
expectancy by 0.19 (0.14–0.23) and 0.90 (0.50–1.21) years, respectively. At optimal cardio-
protective medication use, the projected health gains in these individuals increased by fur-
ther 0.33 (0.25–0.40) and 0.37 (0.20–0.50) years, respectively. Limitations include risk
factor measurements from the UK routine primary care database and limited albuminuria
measurements.
Conclusions
The CKD–CVD policy model is a novel resource for projecting long-term health outcomes
and assessing treatment strategies in people with reduced kidney function. The model indi-
cates clear survival benefits with cardioprotective treatments in this population and scope
for further benefits if use of these treatments is optimised.
Author summary
Why was this study done?
• Chronic kidney disease (CKD) is highly prevalent, and even mildly reduced kidney
function increases cardiovascular and kidney disease risks and mortality.
• In people with CKD, reducing cardiovascular risk with widely available effective cardio-
protective treatments (i.e., statins, hypertensives, and antiplatelets) is a key target.
• Lifetime policy models are needed to project long-term health outcomes and costs and
prioritise treatment strategies.
What did the researchers do and find?
• We used a large UK population healthcare database to identify a large open cohort
(2005–2013) of 1.1 million individuals with reduced kidney function.
• We developed a policy model that projects the decline of kidney function, cardiovascu-
lar disease (CVD), mortality, healthcare costs, and quality of life using an individual’s
characteristics.
• The model achieved good risk discrimination and accurately predicted risks of cardio-
vascular events in patient categories by kidney function impairment (estimated glomer-
ular filtration rate [eGFR] 60–89; 45–59; 30–44; 15–29; and <15 mL/min/1.73 m2 not
on renal replacement therapy [RRT]) and by 10 geographic regions in England.
PLOS MEDICINE A policy model for people with reduced kidney function
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003478 December 16, 2020 2 / 19
allow us to distribute patient data to other parties.
Researchers may apply for data access at http://
www.CPRD.com/. Software and codelists
availability The R code of the CKD-CVD policy
model (License: MIT License) and the codelists to
specify disease endpoints and patient
characteristics using CPRD data are available at
http://www.herc.ox.ac.uk/downloads/
supportingmaterial. The R code of the CKD-CVD
policy model is also available from https://github.
com/ischlackow/CKD-CVD-policy-model. The
standalone R code of the CKD progression model
is provided in the CKD submodel manuscript[20].
Funding: The research was funded by the National
Institute for Health Research (NIHR) Programme
Grants for Applied Research programme
(Reference: RP-PG-1210-12003); with RP as the PI
and RS as a co-PI; website https://www.nihr.ac.uk/
explore-nihr/funding-programmes/programme-
grants-for-applied-research.htm RP, RH and BM
acknowledge support by the NIHR Oxford
Biomedical Research Centre. https://oxfordbrc.nihr.
ac.uk/ RP and RH receive funding from the NIHR
Collaboration for Leadership in Health Research
and Care (CLARHC; https://www.clahrc-oxford.
nihr.ac.uk/) Oxford and the NIHR Oxford Medtech
and In-Vitro Diagnostics Co-operative (MIC; https://
www.community.healthcare.mic.nihr.ac.uk/). DL
receives funding from the NIHR Applied Research
Collaboration (ARC) West Midlands and NIHR
Oxford MIC, hosted by Oxford Health NHS
Foundation Trust. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: RP declares being
the PI of NIHR funded Programme of work to
evaluate how to monitor CKD in Primary Care
which part-funded his salary as well as members
of the research team.
Abbreviations: AIC, Akaike information criterion;
BMI, body mass index; CI, confidence interval;
CKD, chronic kidney disease; CKD–CVD, chronic
kidney disease–cardiovascular disease; CKD-EPI,
Chronic Kidney Disease Epidemiology
Collaboration; CPRD, Clinical Practice Research
Datalink; CVD, cardiovascular disease; eGFR,
estimated glomerular filtration rate; HES, Hospital
Episodes Statistics; ICD-10, International Statistical
Classification of Diseases and Related Health
Problems 10th Revision; ISAC, Independent
Scientific Advisory Committee; KDIGO, Kidney
Disease Improving Global Outcomes; MI,
myocardial infarction; NICE, National Institute for
Health and Care Excellence; ONS, Office for
• To illustrate model use in this population, we assessed survival benefits with partial
(0.06–1.25 extra years per person across patient categories) and optimal (0.10–0.55 extra
years per person across patient categories) use of cardioprotective treatments.
What do these findings mean?
• The model can be used to project long-term health outcomes in people with reduced
kidney function and assess value of a range of treatment strategies. Further efforts to
improve the use of cardioprotective medication are likely to improve life expectancy in
this population.
Introduction
Chronic kidney disease (CKD) affects over 250 million people worldwide [1,2], with preva-
lence expected to increase with rising levels of obesity and diabetes and ageing populations.
This progressive disease is associated with increased risk of cardiovascular disease (CVD) and
all-cause mortality [3–5], and most people with CKD die before reaching end-stage renal dis-
ease [6]. Excess CVD mortality has been reported even in people with only mildly reduced kid-
ney function and prior to the clinical diagnosis of CKD [7]. Since kidney function typically
declines slowly over time, people may spend many years with mild or moderate disease [8]
and at increased CVD risk. Timely CVD prevention is a key treatment target, with growing
efforts to optimise treatments and develop new therapies across the spectrum of people with
kidney impairment. Long-term disease models are, therefore, needed to guide the assessment
of the net effects and cost-effectiveness of different management regimens.
The available long-term models for people with reduced kidney function, however, are
either derived from a range of literature sources with limited ability to assess variation of
effects across people at different disease risks [9–13] or consider only populations with moder-
ate to advanced CKD [5], whereas the vast majority of patients seen in primary care have only
mildly reduced kidney function (estimated glomerular filtration rate [eGFR] of 60 to 89 mL/
min/1.73 m2 [14]). Routine healthcare data are now available to inform models of the neces-
sary complexity to address key policy questions across the spectrum of patients with reduced
kidney function.
We present an internally validated lifetime policy model for people with reduced kidney
function (eGFR<90 mL/min/1.73 m2), developed using the detailed individual patient data
from a UK population-based primary care database, the Clinical Practice Research Datalink
(CPRD), linked with secondary healthcare data (Hospital Episodes Statistics [HES]), mortality
registries, and social deprivation data. The model overcomes many of the limitations of previ-
ous models and projects decline of kidney function, experience of cardiovascular events and
mortality, as well as health-related quality of life and healthcare costs across the range of people
with reduced kidney function.
Methods
This study is reported as per Transparent Reporting of a multivariable prediction model for
Individual Prognosis Or Diagnosis (TRIPOD) Checklist for Prediction Model Development
and Validation (S1 Checklist) [15].
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National Statistics; QALY, quality-adjusted life year;
RRT, renal replacement therapy; TRIPOD,
Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis;
uACR, urinary albumin-to-creatinine ratio.
Data
The CPRD is a database of routine primary care records in the UK (674 practices; 11.3 million
people) [16]. For the present analyses, data from the 388 practices in England with CPRD data
linked to (a) UK HES, containing dates of admission and the International Statistical Classifi-
cation of Diseases and Related Health Problems 10th Revision (ICD-10) codes at discharge for
each hospital episode, including up to 99 secondary discharge codes; (b) mortality data from
Office for National Statistics (ONS), containing up to 15 ICD-10 codes for contributing causes
of death; and (c) Townsend socioeconomic deprivation quintiles were used.
Study population
We derived an open cohort of adult patients (�18 years of age) who were registered at “up-to-
standard” CPRD practices (i.e., meeting the CPRD standard for continuity of recording and
number of recorded deaths) between January 1, 2005 and December 31, 2013 and were
deemed to have acceptable patient records (based on continuous registration status, good qual-
ity recording of events, and valid age and gender). Patients who were pregnant in the 12
months preceding cohort entry or have had renal transplantation or were on maintenance
dialysis at any time prior to cohort entry were excluded. To be included in the study cohort, a
patient had to have (at least) 2 eGFR tests<90 mL/min/1.73 m2 at least 90 days apart, in line
with the definitions used in Kidney Disease Improving Global Outcomes (KDIGO) classifica-
tion [14] and the National Institute for Health and Care Excellence (NICE) [17]. All available
data after (the latest of) the patient’s current registration date, the date the practice became up
to standard, and prior to study start date were used to define eligibility. To ensure adequate
recording of baseline covariates, eligible patients had to be registered with the practice for a
minimum of 12 months prior to cohort entry. Hence, the cohort entry date for each patient
was the latest of the study start date (January 1, 2005), practice up-to-standard date, date of
18th birthday, date of registration with the practice plus 12 months, and date of the second eli-
gible (<90 mL/min/1.73 m2) eGFR test. Patient records were censored at the earliest of the
study end date (December 31, 2013), date of last upload of practice or linked data, date of
death, transfer out of practice date, and date of incident record of pregnancy within study
period.
In accordance with the KDIGO classification [14], at cohort entry, participants were catego-
rised according to the value of their second eligible eGFR test as follows: G2 (eGFR 60 to 89
mL/min/1.73 m2); G3a (eGFR 45 to 59 mL/min/1.73 m2); G3b (30 to 44 mL/min/1.73 m2); G4
(eGFR 15 to 29 mL/min/1.73 m2); and G5 (eGFR<15 mL/min/1.73 m2) not on renal replace-
ment therapy (RRT; defined as being with renal transplantation or on maintenance dialysis).
The eGFR values were calculated from creatinine using the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation [18] as recommended by NICE [17].
The lifetime CKD–CVD policy model
This section contains a brief description of the model development methods. Full details are
reported in Methods A in S1 Text. The lifetime chronic kidney disease–cardiovascular disease
(CKD–CVD) policy model is a decision-analytic model, consisting of a CKD submodel, which
projects kidney function, and a CVD/nonvascular death submodel, which projects the experi-
ence of fatal and nonfatal CVD events and nonvascular death (Fig 1). Covariates in the model
were defined using the standard clinical terminology system used in the UK general practices,
namely the Read Codes and/or other data categories (e.g., entity codes). Cardiovascular events
and deaths were defined using both Read and ICD-10 codes (see section “Software and code-
lists availability” at the end of manuscript). Missing data were imputed using multivariate
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multiple imputation methods or, as in the case of urinary albumin-to-creatinine ratio (uACR),
were assigned into a separate category.
CVD/nonvascular death submodel
To derive the risk equations, two-thirds of the primary care practices were randomly allocated
to the estimation cohort and the remaining one-third to the validation cohort.
The annual risks of 3 nested cardiovascular endpoints: (a) vascular death; (b) vascular death
or stroke; and (c) vascular death, stroke, or myocardial infarction (MI) and the risks of nonvas-
cular death and of first hospitalisation for heart failure were estimated (Fig 1). First event of
each type was modelled, and events that happened before an event of another type contributed
to the estimations (e.g., an MI that occurred before a vascular death would be included as a
risk factor in the vascular death risk equation).
Fig 1. CVD submodel of the CKD–CVD policy model. CKD–CVD, chronic kidney disease–cardiovascular disease; CVD, cardiovascular disease; eGFR,
estimated glomerular filtration rate; HF, heart failure; MI, myocardial infarction.
https://doi.org/10.1371/journal.pmed.1003478.g001
PLOS MEDICINE A policy model for people with reduced kidney function
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003478 December 16, 2020 5 / 19
For each participant, the risks of these endpoints were estimated using survival risk equa-
tions adjusting for a number of baseline characteristics and annually updated age, latest CVD
event (including events that occurred during follow-up), and latest eGFR category during fol-
low-up. Additionally, each risk equation included further adjustments for the use of lipid-low-
ering, antihypertensive, and antiplatelet treatments. Separate risk equations were fitted in
participant categories by gender and previous CVD at cohort entry (binary variable: yes/no) to
acknowledge different contributions of risk factors. Thus, 4 equations were estimated for each
endpoint. Initially, the Andersen–Gill generalisation of the Cox proportional hazards model
was used with all potential covariates included. Age, uACR, kidney disease history, and (for
CVD endpoints only) CVD history were retained in all risk equations regardless of their statis-
tical significance. For other covariates, an automatic forward and backwards selection proce-
dure was used. Finally, the variables judged not significant, both statistically (i.e., p-value
�0.01) and clinically (as advised by clinicians), were removed one at a time, and the resulting
models were compared to the model without the excluded variable using the likelihood ratio
test with p-values <0.01 deemed statistically significant. Subsequently, parametric propor-
tional hazard survival models, including selected variables, were estimated to support the
extrapolation over patient’s lifetime. Exponential, Weibull, and Gompertz proportional haz-
ards models were considered, as both external evidence and the Cox modelling confirmed the
suitability of the proportional hazards methods, with the choice of the survival distribution
guided by minimum Akaike information criterion (AIC)[19].
CKD submodel
The derivation of the CKD submodel is described in detail elsewhere [20]. Briefly, this submo-
del simulates progression through renal function stages (G1 [eGFR�90 mL/min/1.73 m2]/G2,
G3a, G3b, G4, and G5 not on RRT) and death using a hidden Markov model fitted separately
to 4 cohorts of patients by baseline albuminuria status (unmeasured, normoalbuminuria,
microalbuminuria, and macroalbuminuria [14]). Models were adjusted for patient’s sex, diag-
noses of heart failure and cancer at cohort entry, and annually updated age. For the purpose of
the CKD–CVD policy model, the transition to death was replaced with the estimated risk
equations for vascular and nonvascular death as described in the previous section. Addition-
ally, annual transition probabilities from stage G5 not on RRT to dialysis (12% for males <65
years old and 5.5% for males�65 years old; 9.6% for females <65 years old and 2.7% for
females�65 years old) and renal transplantation (4.3% for males <65 years old and 0.1% for
males�65 years old; 3.7% for females <65 years old and 0.1% for females�65 years old) were
calculated in the CPRD study cohort. Annual rates of renal transplantation while on mainte-
nance dialysis (6.1%) and renal transplantation failure resulting in dialysis initiation (1%) were
informed by the UK renal registry data.
Integrated CKD–CVD model structure
The CVD/nonvascular death and CKD submodels were combined into a Markov model with
an annual cycle of transition and transition probabilities between the states derived from the
risk equations, as described in the previous sections. The nonfatal model states were defined
by the patient’s most recent CVD history (stroke, MI in the absence of a stroke, or no event;
CVD/nonvascular death submodel) and the latest eGFR category (G2, G3a, G3b, G4, and G5
not on RRT, with renal transplant, on dialysis). Together, the model states consist of all possi-
ble combinations of nonfatal CVD events and CKD stages with 2 further fatal states (vascular
death and nonvascular death). At start of each annual cycle, patient’s age, CKD stage, and
CVD event status are updated. The information then initially feeds into the CKD submodel, in
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which patient’s next CKD stage is projected, and then into the CVD/nonvascular death sub-
model, in which patient’s CVD status is projected. The model then enters the next annual
cycle, where the updated disease histories and age are used.
The risk equation for heart failure was used in the model to project the impact of heart fail-
ure on health-related quality of life and healthcare costs but not on the subsequent CVD
events.
Health-related quality of life and healthcare costs
Health-related quality of life utilities and annual healthcare costs, corresponding to each
model state, were informed by external data (Tables A and B in S1 Text). Annual healthcare
costs corresponding to earlier years were inflated to year 2017 using the hospital and commu-
nity health services index.
Uncertainty
Parameter uncertainty in the model was propagated by sampling all parameters from prede-
fined probability distributions (multivariate normal distribution for the CVD and CKD risk
equations, binomial distribution for transitions into, and between, renal transplantation and
dialysis, gamma distribution for the cost equation and normal distribution for the quality of
life equation), generating 1,000 sets of risk, cost, and quality of life equations and simulating
the results with these parameter sets. Confidence intervals (CIs) were then derived using the
equal-tailed percentile method.
Model validation
Model-simulated cumulative rates of cardiovascular endpoints were validated by comparing
the simulated cumulative rates with the Kaplan–Meier product limit estimates over 5 years of
follow-up among patients in the validation cohort, by eGFR category at cohort entry. Model
discrimination was assessed using Harrell’s C-index for censored response. Model-simulated
cumulative rates of vascular death, stroke, or MI were also compared with the respective simu-
lated Kaplan–Meier product limit estimates of cumulative rates over 5 years of follow-up sepa-
rately in each of the 10 regions of England, by eGFR category at cohort entry.
Policy applications
The CKD–CVD policy model was used to simulate the remaining life expectancy of people
with reduced kidney function and quantify the contribution of widely used treatments to
reduce cardiovascular risk, namely statins, antihypertensives, and antiplatelets. For these anal-
yses, a random sample of 64,000 patients was sampled from the CPRD cohort. The sampling
was performed separately in groups of patients by gender, previous CVD, and eGFR category
(5,000 each from the categories G2, G3a, and G3b and 1,000 from the combined G4 and G5
not on RRT category) maintaining the age distribution within each group.
Application 1: Predicting remaining life expectancy of people with reduced kidney
function. Firstly, the CKD–CVD model was used to predict remaining life expectancy and
quality-adjusted life expectancy for the sampled cohort using patients’ characteristics at entry
into the cohort and assuming no use of statins, antihypertensives, or antiplatelets.
Application 2: Quantifying the impact of partial and optimal use of cardiovascular pre-
vention medications in people with reduced kidney function. Secondly, the CKD–CVD
policy model was used to project (a) the (quality-adjusted) life expectancy gained with 2013
levels of use of statins, antihypertensives, and antiplatelets [17,21,22] compared to no use; and
PLOS MEDICINE A policy model for people with reduced kidney function
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(b) the additional (quality-adjusted) life years that could be gained with optimal guideline-
indicated use of these cardioprotective medications (compared to partial use). The effects of
these treatments (relative risks) on cardiovascular event risks in the model were informed
from recent meta-analyses of randomised trials [23–25] (Methods A in S1 Text).
Software
All analyses were performed using R or Stata 15 [26,27]. The figures were produced using the
R ggplot2 package [28]; see also “Software and codelists availability” section.
Ethics statement
The protocol for this research was approved by the Independent Scientific Advisory Commit-
tee (ISAC) of the Medicines and Healthcare Products Regulatory Agency (protocol number
14_150RA, available on request). Ethical approval for observational research using the CPRD
with approval from ISAC has been granted by a National Research Ethics Service committee
(Trent MultiResearch Ethics Committee, REC reference number 05/MRE04/87). No consent
was required as the data were analysed anonymously.
Results
The study cohort consisted of 1,139,548 patients with reduced kidney function (Fig A in S1
Text), with a median follow-up of 4.9 years (interquartile range 2.3 to 7.8 years). At entry, the
vast majority of participants were in eGFR categories G2 (74%) or G3a (18%), with only a few
patients in G3b (6%), G4 (1.3%), or G5 not on RRT (0.2%). The baseline characteristics of par-
ticipants in the estimation (Table C in S1 Text) and validation (Table D in S1 Text) cohorts
were broadly similar and confirm increased prevalence of a range of vascular and other comor-
bidities with worsening kidney function. Participants in G5 not on RRT at entry were some-
what younger than other participants with moderate to severe renal impairment, e.g., in the
estimation cohort, the mean age at cohort entry was 71 years among patients in G5 not on
RRT and 81 years among patients in G4 (72 and 81 years, respectively, in the validation
cohort).
During follow-up, larger proportions of participants with greater kidney function
impairment experienced cardiovascular events or died (Table E in S1 Text). For example, in
the estimation cohort, among the participants in eGFR category G2 at cohort entry, 2% died
from cardiovascular causes, and 5% experienced the combined endpoint of vascular death,
stroke, or MI compared with 12% and 22%, respectively, among participants in G5 not on
RRT at cohort entry. Details of transitions between eGFR categories have been published else-
where [20].
Risk equations
The risk equations for the cardiovascular endpoints (vascular death, vascular death or stroke,
vascular death, stroke, or MI) indicated that more severe eGFR categories were associated with
increased cardiovascular risk, with clearly graded associations observed across all eGFR cate-
gories of patients (Tables 1 and 2 for females and males, respectively). A stroke or an MI dur-
ing follow-up also substantially increased the subsequent risk of cardiovascular death, with
stronger proportional increases among patients without previous CVD. Age, type 1 diabetes,
smoking, and history of CVD at cohort entry were also associated with substantially increased
cardiovascular risks. A graded association was observed between worsening eGFR category
PLOS MEDICINE A policy model for people with reduced kidney function
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003478 December 16, 2020 8 / 19
and higher risks of nonvascular death (Table F in S1 Text) and heart failure hospital admission
(Table G in S1 Text).
Model validation
The cumulative incidence of cardiovascular events simulated by the model across the 5 years
of follow-up closely matched the observed rates for most years and eGFR categories of patients
in the validation cohort (Fig 2; Fig B in S1 Text) as well as across the 10 regions in England
(Fig C in S1 Text). The Harrell’s C-index, ranging from 0.60 to 0.84 in the estimation cohort
and from 0.62 to 0.84 in the validation cohort, indicated that the risks of key disease events
were well discriminated across the eGFR categories (Table H in S1 Text).
Application 1: Predicting life expectancy of patients with reduced kidney function.
The model predicted large variation in survival by eGFR category at cohort entry (Fig 3,
Table I in S1 Text). Among patients aged 60 to 69 in G2, those without previous CVD were
predicted to live a further 22.1 years (16.1 quality-adjusted life years [QALYs]) and those with
CVD a further 18.6 years (11.8 QALYs). The corresponding values for patients in G5 not on
RRT were 13.7 years (9.2 QALYs) and 10.1 years (5.7 QALYs), respectively.
Application 2: Quantifying the impact of partial and optimal use of cardiovascular pre-
vention medications in patients with reduced kidney function. Fig 4 and Table J in in S1
Text summarise the benefits of statins, antihypertensives, and antiplatelets by patient’s age,
eGFR category, and history of CVD at cohort entry. Using NICE recommendations in 2019,
the proportions of patients indicated for treatment who were prescribed statin, antihyperten-
sive, or antiplatelet in 2013 would be 37% among those without previous CVD and 71%
among those with previous CVD. The predicted benefits of this level of treatment are substan-
tial across all patient categories, with younger patients with previous CVD deriving largest
benefits. Among patients aged 60 to 69 without previous CVD, the use of these treatments at
2013 levels is evaluated to add a further 0.19 years (0.22 QALYs) to the life expectancy of those
in G2, 0.20 years (0.22 QALYs) in G3a, 0.22 years (0.22 QALYs) in G3b, 0.25 years (0.23
QALYs) in G4, and 0.22 years (0.21 QALYs) in G5 not on RRT. For patients aged 60 to 69
with previous CVD, the gains in life expectancy are higher at 0.90 years (0.80 QALYs) in G2,
0.92 years (0.82 QALYs) in G3a, 1.01 years (0.81 QALYs) in G3b, 1 year (0.78 QALYs) in G4,
and 0.95 years (0.72 QALYs) in G5 not on RRT.
Increasing treatment use to the optimal guideline-indicated levels in 2019 would add fur-
ther 0.33 to 0.43 years (0.35 to 0.39 QALYs) in patients 60 to 69 years old without previous
CVD at cohort entry and between 0.37 and 0.41 years (0.30 and 0.34 QALYs) in patients 60 to
69 years with previous CVD at cohort entry.
Discussion
In the current study, we present a novel policy model of kidney disease progression and car-
diovascular complications in people with reduced kidney function and quantify the benefits of
cardioprotective medications in this population. The model demonstrates good disease risk
discrimination and predictive accuracy and can be used to project the decline in patients’ kid-
ney function, experience of cardiovascular events, healthcare costs, quality of life, and survival
using patients characteristics at entry. To illustrate the model’s potential to inform policy, we
evaluated the gains in (quality-adjusted) survival achieved with partial use of cardioprotective
treatments in patients with reduced kidney function (i.e., at 2013 levels), as well as further
gains that could be achieved with optimised treatments according to current guidelines.
The graded relationships between more severe kidney function impairment and increased
CVD risk and between the experience of cardiovascular events and cardiovascular mortality
PLOS MEDICINE A policy model for people with reduced kidney function
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Table 1. Risk equations for CVD endpoints in the CKD–CVD policy model (females).
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are consistent with reports from other patient data [5]. These associations, estimated separately
in patient categories by sex and previous CVD, are stronger among men and among patients
without history of CVD. This difference in strengths of associations has been previously
reported with respect to effect of cardiovascular events on subsequent cardiovascular risk
[29,30] but is less well studied with respect to the impact of kidney function impairment on
cardiovascular risk, with data typically presented across both sexes [3,31].
The predicted life expectancies using the CKD–CVD policy model were somewhat larger
than the predictions using a previous model, which was informed by data from moderate to
severe CKD patients recruited in hospitals [5], which indicates that the population with
reduced kidney function seen in primary care differs from the CKD patients seen in secondary
care. The CKD–CVD model allowed us to estimate for the first time the population gains in
life expectancy from the use of 3 commonly indicated cardiovascular prevention treatments
Table 1. (Continued)










































Characteristics updated on an annual basis









eGFR category at the end of the














































Cardiovascular event during follow-
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Table 2. Risk equations for CVD endpoints in the CKD–CVD policy model (males).
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(statins, antihypertensives, and antiplatelets) in UK primary care, including the potential for
further gains with the optimised use of these treatments. These projected gains in survival are
consistent with previous analyses of effects of individual interventions such as statins in CKD.
The major strength of our model is that it is based on a large open cohort of unselected pop-
ulation of patients with reduced kidney function from 388 UK primary care practices, with
available information for a wide range of individual patient characteristics. This has helped to
overcome a number of limitations of previously published CKD models. It has assured model
generalisability and allowed assessment of disease risks across individuals with different dis-
ease risks, including people with mild kidney impairment (i.e., prior to the onset of clinical
CKD), which constituted a large part of the cohort. Furthermore, the model demonstrated
good validity, with good discrimination and calibration across eGFR categories and geographi-
cal regions in the cohort.
Table 2. (Continued)
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There are a number of limitations to the model, mostly related to the use of routine data. In
routine healthcare practice, risk factors are measured at points of contact with health services,
and the purpose of data measurement and recording is to support clinical care of patients and
operations of healthcare providers. Therefore, unlike data from prospective studies, the rou-
tinely available data are often clinical indication driven, and missing data are potentially not
missing at random. For example, at entry, albuminuria status was not measured for over half
of the cohort, and in the early years of data, the urine dipstick tests were widely used, with
potential impact on reliability of albuminuria measures [32,33]. In our cohort, having unmea-
sured albuminuria was associated with higher cardiovascular risk compared to having it mea-
sured as normal (Tables 1 and 2), indicating that the category of patients with unmeasured
albuminuria at entry is likely a mixed group of patients with different degrees of albuminuria.
Similarly, we assumed that the absence of a record for a comorbid condition means the
Fig 2. Comparison of cumulative risks predicted by the model and observed Kaplan–Meier risks in the validation cohort for main cardiovascular endpoints
and by eGFR category at cohort entry. CI, confidence interval; CKD, chronic kidney disease; CPRD, Clinical Practice Research Datalink; CVD, cardiovascular
disease; eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy.
https://doi.org/10.1371/journal.pmed.1003478.g002
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absence of the condition. This might not be the case with the absence of a diagnosis of diabetes
or CVD, for example, potentially partially due to limitations in data recording or diagnosis
coding [34,35]. Furthermore, the vast majority of participants in the study cohort were in
eGFR category G2, i.e., had only minor kidney function impairment and no CKD. This cate-
gory of patients might be biased towards patients who had creatinine tests because of another
condition (e.g., diabetes or hypertension) and, while covariates in the model will capture large
differences in risk, model generalisability could be affected by omitted relevant factors. The
much smaller number of participants with more advanced renal impairment, respectively, has
likely contributed to more limited model discrimination in these categories. Further assess-
ments of model performance in patient cohorts external to CPRD, including prospective clini-
cal trials and observational cohorts with regular measurements of kidney function, could
mitigate against the routine data limitations.
Our study has indicated areas where further development will be informative. Firstly, the
evolving model complexity and related computational needs motivated us to limit the number
of endpoints and relationships between them. Future model developments could explore uti-
lising different model structures such as discrete event simulations. These are likely to facilitate
Fig 3. Predicted life expectancy and QALYs in the absence of cardiovascular prevention treatments by CVD history, age, and eGFR category at cohort entry.
CKD–CVD, chronic kidney disease–cardiovascular disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; QALY, quality-adjusted life year;
RRT, renal replacement therapy. The predictions by the CKD–CVD model are based on a random sample of 64,000 patients from the whole cohort; see Methods section
for further detail on how the sampling was performed.
https://doi.org/10.1371/journal.pmed.1003478.g003
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the inclusion of larger number of model endpoints but may substantially increase model com-
putation time and make uncertainty estimation less tractable [36]. Secondly, change in albu-
minuria over time is an important further marker of kidney function, and its inclusion in the
model could enhance model performance and functionality [37]. Unfortunately, the limited
albuminuria data in our database prevented us from following such an investigation.
In conclusion, the lifetime CKD–CVD policy model allows the simulation of long-term kid-
ney function decline, cardiovascular morbidity, vascular and nonvascular mortality, health-
related quality of life, and healthcare costs across the range of patients with reduced kidney
function and overcomes many limitations of previous models. It will contribute to a greater
understanding of the progression of kidney disease and its cardiovascular complications. In
this paper, we have demonstrated its use to project disease risks and survival under particular
treatment strategies, but its applications are wider. The model may be beneficial to health data
scientists, health economists, and policy makers for comparative effectiveness and cost-
Fig 4. Predicted life years and QALYs gained with cardiovascular prevention medications as per (a) use in 2013 compared to no use (black bars) and additional gains
with (b) optimal guideline-indicated use in 2019 (grey bars) by CVD history, age, and eGFR category at cohort entry. CVD, cardiovascular disease; eGFR, estimated
glomerular filtration rate; NICE, National Institute for Health and Care Excellence; QALY, quality-adjusted life year; RRT, renal replacement therapy. The predictions
are based on a random sample of 64,000 patients from the whole cohort. Of the patients indicated for particular cardiovascular prevention treatment in 2019, 37% of
those without CVD and 71% of those with CVD were projected to have been treated in 2013. These proportions were calculated using data on patients that were in the
study cohort in 2013 and the 2019 UK NICE guidelines. See Methods and S1 Methods in S1 Text for more information.
https://doi.org/10.1371/journal.pmed.1003478.g004
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effectiveness assessments in the evaluation of established and novel strategies for the manage-
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